Study #2023-0718
A phase 2 study of the combination TSR-042 with Niraparib in patients with Penile Carcinoma who have progressed following chemotherapy
MD Anderson Study Status
Enrolling
Treatment Agent
Dostarlimab, Niraparib
Description
The purpose of the study is to evaluate the efficacy and safety of the combination of niraparib and dostarlimab in patients participants with advanced relapsed/refractory penile cancer.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Penile Carcinoma
Study phase:
Phase II
Physician name:
Curtis Pettaway
Department:
Urology
For general questions about clinical trials:
1-855-939-4993
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.